Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100, in Soft Capsule.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The primary endpoint was the area under the curve (AUC) of serum 25-hydroxyvitamin-D (25(OH)D) concentrations on Day 112.

This study was conducted in France from February to June 2014 in 53 young adults with a mean age of 26.9 years.

Who Took Part

The study group was 2014 adults.

By PubMed's age tags, the people studied were young adults and adults, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the adults and staff both knew the treatment.

Groups ran in parallel: each of the adults stayed in one arm throughout.

What Was Measured

The primary endpoint was the area under the curve (AUC) of serum 25-hydroxyvitamin-D (25(OH)D) concentrations on Day 112.

At baseline, low mean serum 25(OH)D levels were observed in both groups (10.6 ng/mL in Group 1 and 9.0 ng/mL in Group 2).

The subject headings attached to it are Calcium-Regulating Hormones and Agents, Capsules, Cholecalciferol and Therapeutic Equivalency.

The authors tagged it with the keywords 25(OH)D, oral supplementation and vitamin D.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Vitamin D, K2, Magnesium and Zinc in 2014 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2019 (Nutrients), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.